MCM
DMAC icon

Moore Capital Management’s DiaMedica Therapeutics DMAC Stock Holding History

Moore Capital Management’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-25,000
Closed -$106K – 542
2020
Q3 		$106K Buy
+25,000
New +$132K ﹤0.01% 361

Other funds holding DMAC

SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MHP
Manatuck Hill Partners Westport, Connecticut $370M AUM 95.53% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
JAMONY
Jacob Asset Management of New York Hermosa Beach, California $70.9M AUM 14.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Moore Capital Management's DMAC Position: Q4 2020 in Review

Moore Capital Management sold out of DiaMedica Therapeutics (DMAC) in Q4 2020, closing a stake of 25,000 shares — an estimated $106K sold.

Moore Capital Management first reported a position in DMAC in Q3 2020 and held it in 1 quarter. The position peaked at $106K in Q3 2020. 36 funds tracked by Wall St. Rank hold DMAC as of Q4 2020.

  • Moore Capital Management reported no remaining DiaMedica Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Moore Capital Management sold 25,000 DiaMedica Therapeutics shares in Q4 2020, an estimated $106K.
  • Moore Capital Management first reported a position in DiaMedica Therapeutics in Q3 2020 and held it in 1 quarter.
  • Moore Capital Management's DiaMedica Therapeutics position peaked at $106K in Q3 2020.
  • 36 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q4 2020.

Based on Moore Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.